Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 and Chidamide with Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
NCT06951997Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in pancreatic adenocarcinoma (PDAC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Mar 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06951997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951997.